DOCSLIB.ORG

Drug Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Formulary DRUG FORMULARY QUALIFIED HEALTH PLANS EFFECTIVE JANUARY 1, 2017 LAST UPDATED DECEMBER 1, 2017 INTRODUCTION As a general rule, generic drugs have the lowest This is the Health Alliance Drug Formulary for member copayment. Typically, when a generic Qualified Health Plans (also known as the health enters the market the brand drug moves to Tier 3. insurance “exchange” plans). In order to assist Members who choose the brand name after the members and providers in choosing prescription release of a generic version may pay the copayment drugs for treatment, we encourage members to show plus the difference in cost between the brand and this list to their physicians and pharmacists. In generic drug. Generic drugs can help members save addition, we encourage prescribers to use this list on out-of-pocket medication costs. when considering treatment options. Final decisions regarding treatment options are made between the Generic Equivalent vs. Generic Alternative physician and patient. Generic equivalents are medications that contain the same active ingredient, with the same strength The formulary is subject to change at any time. and dosage form as the brand medication. Generic Members can access the most up-to-date version of equivalents are as safe and effective and produce this list by visiting HealthAlliance.org. Members the same results as the brand counterpart. can also log in to YourHealthAlliance.org to check specific drug coverage and pricing information. The Generic alternatives can produce the same formulary does not provide information about an intended effect on the body as the comparable individual’s specific coverage. Please refer to your brand. Generic alternatives are medications that plan documents for complete coverage details. work like a particular brand drug and are used to treat the same condition. However, the active HOW TO USE THIS LIST ingredient in a generic alternative is different from This drug list is organized in sections by drug the brand medication. class or medical condition. Within each section are subsections to help locate medications. Talk to Your Doctor Most drugs listed, whether generic or brand, are If your doctor writes a prescription for a brand formulary drugs. drug that does not have a generic equivalent, consider asking if an appropriate generic alternative To search within the PDF, choose the search is available. function, enter a drug name and click “search” or “find.” You can also search using the index, which As a patient, you can tell your pharmacist you lists drugs alphabetically. are interested in generics. In most situations, your pharmacist can substitute a generic equivalent for Generics its brand counterpart without a new prescription Like brand drugs, generic drugs go through an from your doctor. approval process by the Food and Drug Administration (FDA) and must meet similar For more information on generics, visit standards of effectiveness and chemical make-up as AskForGenerics.org. branded drugs. Drugs to Treat Multiple Conditions The main difference between the reference brand Doctors use some drugs to treat more than one drug and its generic equivalent is that the generic medical condition. Within this document, each drug often costs much less. is listed according to its first FDA-approved use. Please check the index if you do not find your medication in the therapeutic class that corresponds to your condition. ph-formularyintroQHP-1217 COVERAGE AND LIMITATIONS B. Documented allergy to a formulary drug, with no other formulary choices Tier Information C. Successfully maintained condition on a specific A drug’s copayment tier indicates what you will drug where switching to an alternative drug may pay for the medication with each fill. cause a health risk: o Antiarrhythmics • The majority of generics are Tier 1. These are o Theophylline products your least expensive prescription drugs. o Seizure medications • Preferred brand-name drugs are Tier 2, the o Antipsychotics lowest brand tier. o Antidepressants • Non-preferred brand-name drugs are Tier 3. • Specialty drugs are in Tiers 4, 5, and 6. o Preferred Specialty drugs are Tier 4 Physicians—Requesting a Medical o Non-Preferred Specialty drugs are Tier 5 Exception o Non-Formulary Specialty drugs are Tier 6 To request a Medical Exception for a medication • Preventive drugs are Tier 7. These are covered on behalf of a member, or to request further at no charge as defined in the plan policy. information, please call the Health Alliance Pharmacy department at 1-800-851-3379, option 4, Your pharmacy benefit includes coverage for or log in to YourHealthAlliance.org. the majority of prescription drugs, though some exclusions may apply. Contraceptive Coverage Under Preventive Health Wellness Benefit Utilization Management A female member age 10–50 years old has coverage Some drugs on this list require utilization of some FDA-approved contraceptives for no out- management (UM), i.e. preauthorization, managed of-pocket cost. dose limitations and step-therapy. If UM applies to a drug, it is indicated with one of the following Free contraceptives are listed below: symbols in the column next to the drug name. • Tier 1 oral contraceptives • Limit of three units on condoms (male or • MDL- Managed Dose Limitations female) • PA- Preauthorization • Limit of 2.7 units of spermicidal product • ST- Step-Therapy Only one Tier 1 prescription drug (like a generic NOTE: Effective 8/1/17, most specialty oral contraceptive) or one over-the-counter (OTC) medications used during cancer treatment will product (like male and female condoms or require your doctor to submit for preauthorization spermicides) is covered per 30-day period for no through eviCore. Please click on the link below for cost to the member. a list of these medications: Brand-name contraceptives that are Tier 2 or eviCore Preauthorization List higher are covered with the appropriate member cost share/quantity restrictions according to the These medications are also indicated in our member’s plan. Specialty Drug List. Emergency contraception is covered at Tier 1 Medical Exception using generic levonorgestrel/ethinyl estradiol- Medical exception is a process for reviewing containing products. Brand-name emergency coverage for drugs not on our formulary. Members contraception is covered according to the may qualify for a medical exception if they meet member’s plan. one of these: Quantities above a 30-day supply, including A. Documented failure of all formulary drugs vacation overrides and commercially available within the same therapeutic class extended-cycle contraceptives (like Seasonale), are subject to appropriate member cost-sharing according to the member’s plan. General Exclusions Blood Glucose Monitors FREE By Mail A. Over-the-counter (OTC) medications and their Members with diabetes are eligible to receive a equivalents are not covered, unless otherwise FREE blood glucose meter if they choose one of the specified within the Formulary. Nicotine preferred meters listed below and obtain the meter smoking-cessation products (e.g., transdermal by mail. If a member picks up a blood glucose nicotine, nicotine gum, nicotine inhaler) meter at their local pharmacy, the member’s Tier 2 coverage is based on specific member benefits. copayment will apply when obtained with a B. Any drugs used for cosmetic purposes are not prescription. Free meters are limited to one meter covered. per member per year. The FreeStyle InsuLinx C. Experimental drugs, or any drug product used in System is limited to one meter every three years. an experimental manner, are not covered. D. Replacement of lost or stolen medication is not Freestyle Lite® and Freestyle InsuLinx® covered. ® E. Non-self-administered injectable drugs, unless FreeStyle Lite System FreeStyle Freedom Lite® System otherwise noted, are not covered through the ® pharmacy benefit. Refer to your description of FreeStyle InsuLinx System coverage materials for details. To get an Abbott product, call 1-866-224-8892 F. Foreign drugs and drugs not approved by the and use Offer Code ZD218BKX. FDA are not covered. Or visit www.choosefreestyle.com and enter G. Drugs used to treat erectile dysfunction. Offer Code ZD218BKX. InsuLinx systems are limited to one free PHARMACY SAVINGS PROGRAMS product per member every three years. Health Alliance offers members several programs to lower the drug costs and to help members take their Not all benefit plans include each of the programs medications safely and correctly. listed above. Please refer to your description of coverage documents for more detail or contact the Rxtra Pharmacy department at 1-800-851-3379, option 4. Health Alliance members with prescription coverage can save money based on where they have their 30-day-supply of prescriptions filled. CONTACT US Health Alliance Pharmacy Department 301 S. Vine St. The Rxtra program is simple. Urbana, IL 61801-3347 1-800-851-3379, option 4 • Preferred—At Preferred pharmacies, members can get hundreds of common prescriptions FREE. • Preferred Plus—At Preferred Plus pharmacies, members have the same benefits as the Preferred pharmacies mentioned above. In addition, simvastatin, pravastatin, ProAir and Ventolin HFA are FREE. For a list of participating pharmacies and available drugs in the Rxtra program, visit the pharmacy section of HealthAlliance.org. Retail 90 The Retail 90 program allows members to purchase a 90-day supply of maintenance medication at a discounted copayment from participating retail pharmacies. Because this is a voluntary program designed to increase flexibility, members who prefer may continue purchasing the traditional 30-day supply from their pharmacy with their regular copayment. Table of Contents ANTI-INFECTIVES . 1 PENICILLINS . 1 CEPHALOSPORIN . 1 FIRST GENERATION . 1 SECOND GENERATION . 1 THIRD GENERATION . 1 FOURTH GENERATION . 1 MACROLIDES . 1 TETRACYCLINES . 2 QUINOLONES . 2 AMINOGLYCOSIDES . 2 SULFONAMIDES . 2 ANTIMYCOBACTERIAL AGENTS . 2 ANTIFUNGALS . 2 ANTIVIRALS . 3 ANTIMALARIALS . 4 ANTHELMINTICS . 4 MISC. ANTI-INFECTIVES . 4 ANTINEOPLASTICS, ETC . 5 ALKYLATING AGENTS . 5 ANTIBIOTICS . 5 ANTINEOPLASTIC ENZYMES . 5 ANTIMETABOLITES . 5 ANGIOGENESIS INHIBITORS . 5 ANTIBODIES . 5 HORMONAL AGENTS .
Load more

Recommended publications
  • WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T (51) International Patent Classification: SHENIA, Iaroslav Viktorovych [UA/UA]; Feodosiyskyy A61L 15/44 (2006.01) A61L 26/00 (2006.01) lane, 14-a, kv. 65, Kyiv, 03028 (UA). A61L 15/54 (2006.01) (74) Agent: BRAGARNYK, Oleksandr Mykolayovych; str. (21) International Application Number: Lomonosova, 60/5-43, Kyiv, 03189 (UA). PCT/UA20 16/0000 19 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2016 (15.02.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, a 2015 01285 16 February 2015 (16.02.2015) UA PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, u 2015 01288 16 February 2015 (16.02.2015) UA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Therapeutic Options to Minimize Allogeneic Blood
    Santos AA, etREVIEW al. - Therapeutic ARTICLE options to minimize allogeneic blood Rev Bras Cir Cardiovasc 2014;29(4):606-21 transfusions and their adverse effects in cardiac surgery: A systematic review Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: A systematic review Opções terapêuticas para minimizar transfusões de sangue alogênico e seus efeitos adversos em cirurgia cardíaca: Revisão sistemática Antônio Alceu dos Santos1, MD; José Pedro da Silva1, MD, PhD; Luciana da Fonseca da Silva1, MD, PhD; Alexandre Gonçalves de Sousa1, MD; Raquel Ferrari Piotto1, MD, PhD; José Francisco Baumgratz1, MD DOI: 10.5935/1678-9741.20140114 RBCCV 44205-1596 Abstract Results: Treating anemia and thrombocytopenia, suspending Introduction: Allogeneic blood is an exhaustible therapeutic anticoagulants and antiplatelet agents, reducing routine phle- resource. New evidence indicates that blood consumption is ex- botomies, utilizing less traumatic surgical techniques with moderate cessive and that donations have decreased, resulting in reduced hypothermia and hypotension, meticulous hemostasis, use of topical blood supplies worldwide. Blood transfusions are associated and systemic hemostatic agents, acute normovolemic hemodilu- with increased morbidity and mortality, as well as higher hos- tion, cell salvage, anemia tolerance (supplementary oxygen and pital costs. This makes it necessary to seek out new treatment normothermia), as well as various other therapeutic options have options. Such options
    [Show full text]
  • Management of Bleeding Associated with Malignant Wounds
    JOURNAL OF PALLIATIVE MEDICINE Volume 15, Number 8, 2012 Case Discussions ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2011.0286 in Palliative Medicine Feature Editors: Eva H. Chittenden and Craig D. Blinderman Management of Bleeding Associated with Malignant Wounds Katherine Recka, M.D., Marcos Montagnini, M.D., and Caroline A. Vitale, M.D. Abstract Bleeding malignant wounds in palliative care patients can be anxiety-provoking for patients, their caregivers, and healthcare providers, and can be difficult to manage. We present the case of a 60-year-old man with a bleeding neck wound due to squamous cell carcinoma of the hypopharynx admitted to our inpatient palliative care unit. Management of bleeding included local wound care measures and psychosocial support for the patient and his wife. We review therapeutic approaches to managing bleeding malignant wounds with the aim of providing clinically useful information. Introduction On admission, physical examination revealed a cachectic man with a large ulcerated wound along the angle of his jaw leeding associated with malignant wounds can be from just below his left ear to his tracheostomy. The inferior difficult to manage in all settings, but particularly in aspect of the wound approached the left clavicle. The wound B settings in which goals of care center on comfort and quality of had multiple areas of punctuate hemorrhages and required life. We discuss a challenging case of a patient with a persis- frequent dressing changes to absorb the bleeding. There was no tent bleeding malignant neck wound arising from a stage IV significant odor. His tracheostomy secretions were thick and supraglottic squamous cell carcinoma.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Formulary April
    Standard Formulary MedPerform Medium April, 2021 Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. MedPerform Medium Formulary What is the standard formulary? The MedImpact formulary is a list of covered drugs selected by physician and pharmacist subject matter experts who collaboratively support MedImpact’s Pharmacy and Therapeutics (P&T) Committee. The plan will cover drugs listed in the formulary as long as the drug is indicated for the clinical condition, is prescribed in the appropriate manner, the prescription is filled at a participating network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage. Can the Formulary (drug list) change? Drugs may be added or deleted from the formulary during the year. If a drug is removed from the formulary, [or] adds prior authorization, quantity limits and/or step therapy restrictions on a drug or moves a drug to a higher cost-sharing tier], the plan will notify affected members of the change before the change becomes effective. If the Food and Drug Administration (FDA) deems a drug on the formulary to be unsafe or the drug’s manufacturer removes the drug from the market, the plan will immediately remove the drug from the formulary.
    [Show full text]
  • Guidelines on the Management of Bleeding for Palliative Care Patients with Cancer
    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the management of bleeding for palliative care patients with cancer November 2008 Authors: Dr Bill Hulme and Dr Sarah Wilcox, on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group. Overall objective : To provide evidence-based guidance for the management of bleeding in cancer patients within specialist palliative care. Search strategy: Medline, CINAHL and Embase databases were searched with the help of an experienced librarian using MESH terms for cancer, neoplasm, the generic and trade names for individual drugs and haemorrhage or site-specific areas for haemorrhage. Searches were limited to papers published in English relating to human adults up until March 2008. References obtained were hand searched for additional materials relevant to this review. Additional searches were also conducted for NICE and SIGN guidelines, Cochrane databases, Clinical Knowledge Summaries and publications from associated Royal Colleges. The bulletin board of palliativedrugs.com and palliative medicine textbooks were also reviewed for expert advice. Level of evidence: Evidence regarding medications included in this review has been graded according to criteria described by Keeley [2003] on behalf of the SIGN research group (see appendix 4). Review date: September 2013 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group and are intended for qualified, specialist palliative medicine professionals as an information resource. They should be used in the clinical context of each individual patient’s needs and reference to appropriate prescribing texts / literature should also be made. The Clinical Guidelines Group takes no responsibility for any consequences of any actions taken as a result of using these guidelines.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,050,265 B2 Jamis0n Et Al
    US009050265B2 (12) United States Patent (10) Patent No.: US 9,050,265 B2 Jamis0n et al. (45) Date of Patent: Jun. 9, 2015 (54) VITAMIN CAND VITAMINK, AND (56) References Cited COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR U.S. PATENT DOCUMENTS PROLONGATION OF PROSTHETIC 6,468.414 B1 10/2002 Mahdavi et al. IMPLANT 6,599.945 B2 7/2003 Docherty et al. 7,091,241 B2 8, 2006 Gilloteaux et al. (75) Inventors: James M. Jamison, Stow, OH (US); 2002fO1464637,094.809 A1B2 10,8, 20062002 phyDocherty et al. Thomas M. Miller, El Cajon, CA (US); 2003/0073738 A1 4/2003 Gilloteaux et al. Deborah R. Neal, Uniontown, OH (US); 2007/0043.11.0 A1 2/2007 Gilloteaux et al. Mark Willam Kovacik, Mogadore, OH 2008/0081041 A1 4/2008 Nemeth (US); Michael John Askew, 39S A1 33.9 Miller SA Strongsville, OH (US); Richard Albert 2011/0028436 A1 2/2011 Greenwa Mostardi, Ravenna, OH (US) 2011 0160301 A1 6, 2011 Tsai et al. FOREIGN PATENT DOCUMENTS (73) Assignee: Summa Health System, Akron, OH (US) CN 101537174 9, 2009 JP 2006131611 A 5, 2006 WO O247493 A2 6, 2002 (*) Notice: Subject to any disclaimer, the term of this WO 2007 147128 A2 12/2007 patent is extended or adjusted under 35 WO 2009 118726 A2 10, 2009 (21) Appl. No.: 13/384,574 Bullough, “Metallosis.” J. Joint Bone Surg. Br., 1994, 76, 687-688. Rae, “The toxicity of metals used in orthopaedic prostheses. An experimental study using cultured human synovial fibroblasts.” J. (22) PCT Filed: Jul.19, 2010 Joint Bone Surg.
    [Show full text]
  • Procedure Description Price HC NEWBORN CHARGE STATISTIC
    Procedure Description Price HC NEWBORN CHARGE STATISTIC 0.00 HC ADMISSION CHARGE 584.43 HC ADM HSCRC RATE CHANGE 584.43 HC ANESTHESIA PER MINUTE 2.05 HC ANS HSCRC RATE CHANGE 2.05 HC ANESTHESIA - PAIN MANAGEMENT 2.05 HC ANESTHESIA - SPINE 2.05 HC ANESTHESIA - CARDIAC SURGERY 2.05 HC ANESTHESIA - CARDIOLOGY 2.05 HC ANESTHESIA - DENTISTRY 2.05 HC ANESTHESIA - ELECTROCONVULSIVE THERAPY (ECT) 2.05 HC ANESTHESIA - EMERGENCY SURGERY 2.05 HC ANESTHESIA - GENERAL SURGERY 2.05 HC ANESTHESIA - MEDICINE 2.05 HC ANESTHESIA - NEUROSURGERY 2.05 HC ANESTHESIA - OPHTHALMOLOGY 2.05 HC ANESTHESIA - ORGAN TRANSPLANT 2.05 HC ANESTHESIA - ORTHOPEDICS 2.05 HC ANESTHESIA - OTOLARYNGOLOGY 2.05 HC ANESTHESIA - PEDIATRIC SURGERY 2.05 HC ANESTHESIA - PLASTIC SURGERY 2.05 HC ANESTHESIA - SURGICAL ONCOLOGY 2.05 HC ANESTHESIA - THORACIC SURGERY 2.05 HC ANESTHESIA - TRAUMA GENERAL 2.05 HC ANESTHESIA - UROLOGY 2.05 HC ANESTHESIA - VASCULAR SURGERY 2.05 HC ANESTHESIA - WOMEN'S HEALTH 2.05 HC ANESTHESIA - GASTROENTEROLOGY 2.05 HC ANESTHESIA - ORAL MAXILLOFACIAL 2.05 HC ANESTHESIA - PEDIATRIC MEDICINE 2.05 HC ANESTHESIA - PODIATRY 2.05 HC ANESTHESIA - ANESTHESIA 2.05 HC ANESTHESIA - PEDIATRIC CATH 2.05 HC ANESTHESIA - PEDIATRIC GASTRO 2.05 HC ANESTHESIA - PEDIATRIC HEM ONC 2.05 HC ANESTHESIA - PULMONARY 2.05 HC HYDRATION IV INFUSION INIT 429.60 HC HYDRATE IV INFUSION ADD-ON 214.80 HC THER/PROPH/DIAG IV INF INIT 429.60 HC THER/PROPH/DIAG IV INF ADDON 214.80 HC TX/PROPH/DG ADDL SEQ IV INF 214.80 HC THER/DIAG CONCURRENT INF 35.80 HC TX/PRO/DX INJ NEW DRUG ADDON 107.40 HC IRRIG
    [Show full text]
  • Topical Delivery of Alpha1-Antichymotrypsin for Wound
    Topical delivery of α1-Antichymotrypsin for wound healing Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München vorgelegt von Roland Schmidt aus Treuchtlingen München 2005 Erklärung Diese Dissertation wurde im Sinne von § 13 Abs. 3 und 4 der Promotionsordnung vom 29. Januar 1998 von Herrn Prof. Dr. G. Winter betreut. Ehrenwörtliche Versicherung Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. München, 01. Januar 2005 (Roland Schmidt) Dissertation eingereicht am: 10. Januar 2005 1. Berichterstatter: Prof. Dr. G. Winter 2. Berichterstatter: Prof. Dr. W. Frieß Tag der mündlichen Prüfung: 1. Februar 2005 ACKNOWLEDGMENTS Foremost, I wish to express my deepest appreciation to my supervisor, Prof. Dr. Gerhard Winter. I am much obliged to him for his professional guidance and his scientific support. On a personal note, I especially want to thank him for inspiring my interest in protein pharmaceuticals, for teaching me so much, and for creation of an outstanding working climate. I am also grateful to the Switch Biotech AG, Neuried, Germany for financial support. I would like to acknowledge Dr. Uwe Goßlar for rendering every assistance and the always professional and personally warm contact. Moreover, I would like to thank Annette, Björn, and especially Olivia for performing the Bioassays. Thanks are also extended to Prof. Dr. Bracher, Prof. Dr. Frieß, PD Dr. Paintner, Prof. Dr. Schlitzer, and Prof. Dr. Wagner for serving as members of my thesis advisor committee. I very much enjoyed working at the Department for Pharmaceutical Technology and Biopharmaceutics of the Munich Ludwig-Maximilians-University, what was mainly due to the cooperative and most convenient atmosphere.
    [Show full text]
  • WO 2016/069458 Al 6 May 2016 (06.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/069458 Al 6 May 2016 (06.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/122 (2006.01) A61P 1/18 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/375 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/057336 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 October 2015 (26.10.201 5) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/069,156 27 October 2014 (27. 10.2014) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: SUMMA HEALTH SYSTEM [US/US]; 525 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, E.
    [Show full text]